On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
- CSIMC’S Medical Fee Reform Plan for FY2012 to Promote Faster Patient Discharge, Functional Specialization
February 13, 2012
- FY2012 Medical Fee Revision to Include New Measures to Promote Generic Drug Use
February 13, 2012
- Guidance Fee for Psychiatric Patients to Be Reduced from 55 to 44 Points When Prescribing 3 or More Drugs
February 10, 2012
- Delivery Price Settlement Rate Just 79.1% at End of December: MHLW
February 9, 2012
- Selection Process for Clinical Research Core Hospitals to Begin in Early March
February 9, 2012
- US FDA Warns against Risk of CDAD in Patients Taking PPIs
February 9, 2012
- Drug Discovery Support Organization Needed to Prevent “Decay” of Drug Industry: Mr Hachiyama
February 8, 2012
- Prime Minister Noda Asks Korosho to Study Simultaneous Revisions of Medical, Nursing Fees Every 3 Years
February 7, 2012
- Japan’s Cancer Registry System Lags Behind Other Developed Countries: Mr Umemura of DPJ
February 7, 2012
- Growing Concerns that Premium for New Drug Development May Violate Antimonopoly Act
February 6, 2012
- National, Rosai Hospitals to Enhance Relationship Aiming at Joint Purchasing in July
February 3, 2012
- MHLW to Strengthen Counterfeit Drug Control Creating Public-Private Council
February 3, 2012
- PAFSC's 2nd Committee on Drugs Recommends Approval for Kyowa Kirin's ATL Treatment
February 2, 2012
- Application Based on Data from Public Domain Recommended for Baktar, Flagyl: PAFSC Second Committee
February 2, 2012
- MHLW Presents Tougher Restrictions on Reimbursement of Vitamins
February 1, 2012
- DPJ’s PAL Subcommittee to Discuss Legal Handling of Drugs and Medical Devices
February 1, 2012
- CSIMC General Assembly Establishes Premium for Prescriptions by Generic Name
January 31, 2012
- PAFSC’s First Committee Recommends Designation of Pasireotide Pamoate as Orphan Drug
January 30, 2012
- JPO Decides Lipitor Crystal Form “Valid”, Sandoz Calls for Appeal
January 30, 2012
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…